Cagrilintide + Retatrutide

Ask about this stack

Get a grounded answer across clinical evidence, community patterns, and risks.

Ask AI →

115

authors mention this stack

55

ran the components concurrently

Cagrilintide + Retatrutide (Cagrilintide + Retatrutide) appears in 115 author journeys (55 as actual concurrent use). Common goals: Weight loss and appetite suppression; weight loss; weight loss and appetite suppression. Typical doses reported: Cagrilintide 0.5mg, Retatrutide 5mg. Reported side effects include: unstated Research: 3 studies discuss two or more of these components together (3 clinical); the components appear across 47 studies in total.

Research support

3 research studies discuss two or more of these components together (3 clinical). Per-component literature:

Cagrilintide 13 studies (10 clinical)
Retatrutide 37 studies (26 clinical)

PubMed/PMC articles mentioning each compound in title or abstract.

Typical doses reported

Community-reported doses are not medical guidance.

How people are running it

37

Recommended / discussed

36

Currently running

26

Planning to run

21

Ran in the past

What people use it for

Weight loss and appetite suppressionweight lossweight loss and appetite suppressionappetite suppression and weight lossappetite suppressionweight loss, appetite suppression

Sample reported outcomes

  • unstated
  • Not yet realized
  • Down 63 lbs (SW: 270 lbs, CW: 207 lbs)
  • Suppressed appetite ('can’t think about eating'); down 70 lbs after 6 months
  • Successfully broke through weight loss plateau; weight down from 260 lbs to 198 lbs
  • Zero hunger suppression; felt no effect from either peptide
  • Not yet started
  • successfully maintaining weight at 225 lbs (down from starting weight of 350 lbs)

Self-reported community experiences, not verified results.

Sample reported side effects

  • unstated
  • Not yet realized
  • None specified
  • None
  • Not yet started
  • diarrhea from Cagrilintide, zero fatigue
  • Overactive libido, nausea/aversion to fried food
  • unspecified